Abstract
It is known that the 70 kDa heat shock protein (Hsp70) is localized on the membranes of cancer cells and can serve as a target for tumor theranostics. When developing new generation drugs, priority is given to drugs for "targeted" therapy. The most interesting and promising objects in this area of pharmacology are therapeutic antibodies that directly interact with the pathogen molecule, neutralizing its effects. The present study investigated the antitumor activity of the 8D1 monoclonal antibody, specific to the membrane-associated form of Hsp70, in an in vivo model of mouse myeloma Sp2/0. It was shown that the introduction of the antibody increased the expected lifespan of animals by approximately 20% compared to the control group. The possibility of enhancing the action of the 8D1 antibody has been demonstrated on an in vitro model of suppressing the viability of human lung carcinoma cell line A549 using a conjugate of this antibody with doxorubicin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
